Proven design and performance offer a broad set of options to treat a wide range of patient anatomies. The Valiant™ Captivia™ thoracic stent graft system is designed to treat all lesions of the descending thoracic aorta, including thoracic aortic aneurysms (TAA), type B aortic dissection (TBAD), intramural hematoma (IMH), penetrating atherosclerotic (PAU), and blunt thoracic aortic injury (BTAI). Valiant™ Captivia™ system maintains a continuous seal in a dynamic environment for control and accurate placement.
Product details
Deploy durability with Valiant™ Captivia™ system
Valiant™ Captivia™ thoracic stent graft system maintains vessel wall apposition and fixation, regardless of angulation and oversizing.1 Clinically supported by low type Ia endoleak rate (0% at 5 years).2 The stent graft system has over a decade of worldwide experience and chosen for over 150,000† patients worldwide. It has five years of clinical data across all descending thoracic aortic pathologies.2–4
Case image courtesy of Dr. Roy M. Fujitani, M.D.
The Valiant™ Captivia™ stent graft is the only device that maintains complete apposition regardless of angulation and oversizing.1
Results
The Valiant™ Captivia™ stent graft system remained apposed to the aortic wall at each increment of neck angulation and degree of oversizing in a simulated environment.
For the other stent grafts tested, lack of device wall apposition was observed between the proximal anchorage segment and the inferior aortic wall.
Angular Flexibility and Radial Strength Give the Valiant™ Captivia Stent Graft Conformability and Optimal Seal1
ꝉ10–19% device oversizing.
Risks associated with TEVAR procedures may include rupture, conversion to open repair, or secondary procedures.
Product tested
Proximal apposition at different landing zone angulation
Body apposition at different landing zone angulation
Medtronic Valiant™ Captivia™ system
No lack of apposition (remained apposed)
No lack of apposition (remained apposed)
A
Lack of apposition above 120º
No lack of apposition (remained apposed)
B
No lack of apposition (remained apposed)
Lack of apposition above 110º
C
Lack of apposition above 110º
No lack of apposition (remained apposed)
Features
How does Valiant™ Captivia™ system maintain a continuous seal in a dynamic environment?
Achieving and maintaining a continuous seal is critical for TEVAR durability.
The Valiant™ Captivia™ system establishes and maintains a continuous seal and optimizes apposition in a dynamic environment.
It is the only device that maintains complete vessel wall apposition regardless of angulation and oversizing.1
Continuous seal
8 peak proximal stent design ensures even distribution of radial force for complete vessel wall apposition.
Mini support spring enhances proximal apposition and seal.
Ease of access
Crossing profile is similar to or lower than other thoracic stent grafts for ease of access.
Platinum-iridium Figur8 markers provide high visibility for accurate placement.
Three-step deployment with tip capture release provides controlled deployment and precise placement in the thoracic aorta.
Step 1
Slow, controlled deployment for precise placement
Step 2
Quick deployment option, if desired
Step 3
Tip capture release
Absence of a longitudinal bar allows for enhanced flexibility and kink resistance.
Broad selection of proximal and distal components leads to many combinations to customize for a variety of patients.
Physicians’ perspectives
Clinician experiences with Valiant™ Captivia™ video (03:47)
Watch this video to hear leading clinicians discuss why they choose the Valiant™ Captivia™ stent graft system for their patients.
Dr. Frank Arko accuracy video (03:15)
See how the three-step Captivia™ delivery system enables simple graft adjustment and precise placement within the thoracic aorta.
Dr. Jean Panneton conformability video (03:42)
Watch this video and hear Dr. Panneton discuss how Valiant™ Captivia™ is highly flexible and conformable due to its sinusoidal shape, super‑elastic nitinol springs, and lack of a longitudinal bar.
Dr. Hitoshi Matsuda dissection video (02:50)
Watch this video and hear Dr. Matsuda review a type B aortic dissection case he treated with TEVAR, which provides a minimally invasive alternative to open surgical repair.
Indications
The Valiant™ thoracic stent graft with the Captivia™ delivery system is indicated for the endovascular repair of all lesions of the descending thoracic aorta (DTA) in patients having the appropriate anatomy, including:
Iliac or femoral artery access vessel morphology that is compatible with vascular access techniques, devices, or accessories;
Nonaneurysmal aortic diameter in the range of 18 mm to 42 mm (fusiform and saccular aneurysms/penetrating ulcers), or 18 mm to 44 mm (blunt traumatic aortic injuries) or 20 mm to 44 mm (dissections); and
Nonaneurysmal aortical proximal and distal neck lengths ≥ 20 mm (fusiform and saccular aneurysms/penetrating ulcers), landing zone ≥ 20 mm proximal to the primary entry tear (blunt traumatic aortic injuries, dissections). The proximal extent of the landing zone must not be dissected.
TM* Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
† Data on file. Internal global finance report, total Valiant Captivia cases.
Canaud L, Cathala P, Joyeux F, Branchereau P, Marty-Ané C, Alric P. Improvement in conformability of the latest generation of thoracic stent grafts. J Vasc Surg. 2013;57(4):1084–1089.
Conrad MF, Tuchek J, Freezor R, et al. Results of the VALOR II trial of the Medtronic Valiant Thoracic Stent Graft. J Vasc Surg. 2017;66(2):335–342.
Bavaria J., Brinkman, W., Hughes, C., et al. "Five-year outcomes of endovascular repair of complicated acute type B aortic dissections". J Thorac Cardiovasc Surg. 2020; S0022-5223(20)31092-8. doi: 10.1016/j.jtcvs.2020.03.162.
Patel, H., Azizzadeh, A., Matsumoto, A., Five-Year Outcomes From the United States Pivotal Trial of Valiant Captivia Stent Graft for Blunt Aortic Injury, Ann Thorac Surg. 2020;110:815-20.
